Kinetics

Kinetics Noise Control Unveils Revamped Room Acoustics Website for Enhanced User Experience

Retrieved on: 
onsdag, april 10, 2024
Room acoustics, Room, Acoustics, Marketing, Navigation, Kinetics

DUBLIN, Ohio, April 10, 2024 /PRNewswire-PRWeb/ -- Kinetics Noise Control Inc. (Kinetics), a Catalyst Acoustics Group company and manufacturer of the largest selection of noise control products and solutions, announces the launch of its newly redesigned Room Acoustics website.

Key Points: 
  • Kinetics Noise Control has relaunched its Room Acoustics website with a fresh and streamlined look, featuring a modernized layout across nearly 50 pages within the prominent division.
  • DUBLIN, Ohio, April 10, 2024 /PRNewswire-PRWeb/ -- Kinetics Noise Control Inc. (Kinetics), a Catalyst Acoustics Group company and manufacturer of the largest selection of noise control products and solutions, announces the launch of its newly redesigned Room Acoustics website.
  • Key highlights of the website upgrade include:
    Enhanced User Experience: The new layout ensures a user-friendly interface, allowing visitors to effortlessly explore the diverse range of Room Acoustics products and solutions.
  • This includes informative content about the benefits and applications of Kinetics Noise Control's acclaimed Room Acoustics solutions.

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St

Retrieved on: 
måndag, april 1, 2024
Lung cancer, Survival, Immunotherapy, Disease, Colorectal cancer, Progression-free survival, Medicine, Patient, Common, DNA, Aes, Cancer, Death, Doctor of Philosophy, Gritstone bio, MD, Kinetics, Induction chemotherapy, MSS, Circulating tumor DNA, VAF, Melanoma, PFS, Vaccine, Data, UCLA, Liver disease, Neoplasm, Pharmaceutical industry

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. Overall progression free survival (PFS) data show an early trend in benefit for GRANITE patients (HR=0.82, [95% CI, 0.34-1.67]; 62% censored) and extended PFS benefit in high-risk patients (HR=0.52 [95% CI, 0.15-1.38]; 44% censored), in whom progression occurs faster. Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).

Key Points: 
  • Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).
  • “Today's preliminary Phase 2 results are highly encouraging and represent the first randomized trial evidence, albeit early, that a personalized neoantigen-directed vaccine can potentially drive efficacy in a metastatic ‘cold’ tumor.
  • Fortunately, long-term analysis demonstrates the expected correlation of ctDNA with clinical benefit and favors GRANITE patients.
  • This analysis was performed on 44 patients who received study treatment (control and GRANITE arms) and have available baseline ctDNA data.

Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans

Retrieved on: 
måndag, april 1, 2024
CSF, Tmax, AUC, Patient, Cerebrospinal fluid, Cmax, Kinetics, APP, SILK

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor of amyloid precursor protein (APP) in patients with early Alzheimer’s Disease (AD).

Key Points: 
  • Buntanetap is an oral molecule that selectively binds to an iron-responsive element in the mRNA of APP and other neurotoxic proteins and inhibits their translation.
  • Through this mechanism, buntanetap was shown to decrease the production of amyloid beta (Aβ), a key hallmark in AD.
  • Here, SILK was used to measure the kinetics of APP in early AD patients and to quantify Aβ40 in CSF.
  • Notably, the analysis of adverse events demonstrated no dose-dependent effect of buntanetap compared to placebo, affirming the drug’s safety and tolerability.

Liberty Gold Reports Phase 4 Metallurgical Column Leach Results and Final Phase 5 Metallurgical Drill Assays at its Black Pine Oxide Gold Project, Idaho

Retrieved on: 
torsdag, mars 14, 2024
4C, Database, Silver, Associate, ICP, LGD, Gold, Kinetics, Carbon, TSX, PQ, OTCQX, Metallurgy, CIL, Sodium cyanide, Map, Composite

Additionally, final assay results are released on the remaining 4 metallurgical core holes drilled in 2023 to provide samples for the Phase 5 metallurgical test program.

Key Points: 
  • Additionally, final assay results are released on the remaining 4 metallurgical core holes drilled in 2023 to provide samples for the Phase 5 metallurgical test program.
  • Jon Gilligan, President & Chief Operating Officer for Liberty Gold said, “The results of this latest phase of metallurgical column testwork add key infill data to the gold recovery model at Black Pine.
  • Phase 4B and 4C composites and the pending Phase 5 variability test program filled gaps in the Black Pine resource metallurgical database.
  • Gold and silver were recovered from column leach pregnant solutions by passing it through a small (separate) column containing activated carbon.

LGM Pharma Unveils Enhanced Analytical Testing Services and Expands CDMO Portfolio with Additional Suppository Manufacturing Capabilities

Retrieved on: 
onsdag, mars 13, 2024
Other Manufacturing, Research, Packaging, Clinical Trials, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, CDMO, Growth, ATS, ICP-OES, Patient, LGM, History, ICP-MS, Kinetics, Senior, Doctor of Philosophy, Nausea, Quality, Traction, API, Operation, Fine chemical

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.

Key Points: 
  • LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced a significant enhancement of its capabilities: a 50% expansion and an investment exceeding $2 million in its standalone offering for Analytical Testing Services (ATS) alongside the introduction of new suppository manufacturing capabilities to its contract development and manufacturing (CDMO) portfolio.
  • With a broad array of analytical testing capabilities for small-molecule drug substances and drug products, LGM Pharma can meet the demands of large and small clients, from established pharmaceutical companies to start-ups.
  • In addition to analytical testing, the company provides comprehensive method development and validation services, as well as stability testing, including real-time and accelerated stability studies.
  • “As patient needs become increasingly diversified, the pharmaceutical industry needs CDMO partners that can provide specialized capabilities,” said Ian Gibson, Executive Vice President of Operations at LGM Pharma.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
onsdag, februari 28, 2024
Fast Track, HCV, BID, Patient, Week, Research, Infection, Tax, Doctor of Philosophy, NS5A, FDA, Food, Security (finance), SVR4, Kinetics, Immunodeficiency, Hospital, Standard of care, Viral, Cirrhosis, Interim, Prevalence, Safety, COVID-19, Contraindication, Death, Administration, Atea, Bemnifosbuvir, Risk, DSMB, Second generation, Development, Ageing, SOC, SVR, Viral load, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • Enrollment of the remainder of this study is ongoing with topline results anticipated in the second half of 2024,” continued Dr. Sommadossi.
  • Final results from the 60 patient lead-in cohort confirmed a 98% SVR4 rate across GT from 58 of 59 patients.
  • Final SVR12 results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • Cash, Cash Equivalents and Marketable Securities: $578.1 million at December 31, 2023 compared to $646.7 million at December 31, 2022.

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
onsdag, februari 28, 2024
Active, VSIG4, MSS, National Cancer Institute, Society, Sensei, Lung cancer, Patient, Immunotherapy, Trial of the century, Head, Neoplasm, VISTA, SITC, MBA, Annual general meeting, Therapy, Histology, Biology, NSCLC, ESMO, Kinetics, CRC, PD-1, Conference, Safety, Cemiplimab, Pharmacokinetics, CRADA, CD39, IND, Colorectal cancer, Translation, NCI, Aes, Part-time, FDA, Research and development, Administration, KOL, Cancer, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Eldorado Announces 2024 Detailed Production & Cost Guidance; Provides Four-Year Growth Profile

Retrieved on: 
torsdag, februari 22, 2024
Total, Copper, Sigma, Zinc, MD, Growth, C6, Technical report, Plant, Kinetics, Triangle, Gold, Lead, Public expenditure, Montgolfier brothers, C7, Abitibi, Silver, Negotiation, AISC, Uranium mining

Gold production in 2024 is expected to be between 505,000 to 555,000 ounces, a 9% increase from 2023 gold production (based on the mid-point of the range).

Key Points: 
  • Gold production in 2024 is expected to be between 505,000 to 555,000 ounces, a 9% increase from 2023 gold production (based on the mid-point of the range).
  • Exploration and evaluation expenses are expected to be $27 to $30 million in 2024, with 65% expensed, and 35% capitalized.
  • In 2024, production guidance of 175,000 to 190,000 ounces at the Lamaque Complex is consistent with the previously guided range of 180,000 to 190,000 ounces.
  • Gold production of 675,000 to 735,000 ounces by 2027, resulting in growth of 45% over the four-year period from 2023 production and a compound annual growth rate of over 9%.

Akston Biosciences' AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform's Versatility

Retrieved on: 
måndag, februari 26, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Biotechnology, Veterinary, MERS, Dengue fever, Atopic dermatitis, Kinetics, RBD, Vaccination, Immunoglobulin G, Chronic pain, Nerve growth factor, Dementia, Protein, Infection, CGMP, Notifiable disease, Immune system, Vaccine

This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.

Key Points: 
  • This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.
  • Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures and low-cost, high-volume manufacture.
  • AKS-452 is a subunit vaccine consisting of an Fc fusion of the SARS-CoV-2 spike protein receptor binding domain (SP/RBD).
  • “Akston has also made significant strides in demonstrating the Ambifect® platform's potential beyond infectious disease vaccination,” said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

Cyclic Peptide Synthesis for Drug Discovery: Uses, Benefits and Challenges, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
torsdag, februari 29, 2024
Compound, Peptide, Drug discovery, Kinetics, Fine chemical

TORONTO, Feb. 29, 2024 /PRNewswire-PRWeb/ -- In 2023, peptide-based drugs continued to gain prominence, and three out of six new peptide drug approvals were for cyclic peptides due to their favorable drug properties, such as cell permeability, proteolytic stability and binding kinetics. Cyclic peptides, however, often result in challenging projects due to the difficulty of synthesis or time constraints.

Key Points: 
  • The attendees will also gain insights into cyclic peptides and potential issues in using them for drug discovery.
  • Moreover, they will get to learn about issues with ring strain and what to look for/be aware of when working with cyclic peptides.
  • This session is ideal for anyone interested in cyclic peptide synthesis and its role in drug discovery.
  • Register for this webinar to understand the challenges and strategies for synthesizing cyclic peptides and understand its role in drug discovery.